Human Fetal Tissue Research (NIH Policy Framework)

Human fetal tissue (HFT) research is research that uses tissue or cells obtained from a deceased human embryo or fetus, typically following a pregnancy loss. This entry covers the U.S. federal statutory and NIH policy framework that specifically governs HFT obtained from induced (elective) abortions when federal funding is sought — a distinct, additional layer on top of the general human-subjects protections in the Common Rule (45 CFR 46) and its Subpart B provisions on research involving material obtained after delivery. As with CASRAI’s entry on the NIH Guidelines for Human Stem Cell Research, this entry describes the oversight and funding-eligibility mechanism itself, not the underlying ethical or political debate over fetal tissue research, which has been genuinely contested and has produced several federal policy reversals described below.

Statutory basis: the NIH Revitalization Act of 1993

The federal statutory foundation for NIH-supported HFT transplantation research is the NIH Revitalization Act of 1993, codified at 42 U.S.C. §289g-1 and §289g-2. §289g-1 authorizes the HHS Secretary to conduct or support research on the transplantation of human fetal tissue for therapeutic purposes and requires NIH to report annually to Congress on funded transplantation research using such tissue. §289g-2 sets prohibitions around procurement, including a bar on obtaining human fetal tissue for valuable consideration and restrictions on directing a donation to a specific recipient. The statute’s transplantation-research focus is why NIH and HHS policy notices, rather than the statute itself, have done most of the work of extending and adjusting funding conditions for the broader category of HFT research.

Informed consent and donation requirements

§289g-1(b) sets conditions specific to how tissue is obtained and consented to, independent of the general Common Rule informed-consent requirements that also apply to any associated human-subjects research. In broad terms, the statutory scheme requires that the donating woman’s decision to terminate her pregnancy be made, and attested to in writing, before she is approached about tissue donation, so that the two decisions are kept separate; that no alteration to the timing, method, or procedures of the abortion be made for the purpose of obtaining tissue; and that no payment beyond reasonable costs be made for the tissue itself. §289g-1(b) is also the statutory hook for the Ethics Advisory Board mechanism described below: it provides that the HHS Secretary may not withhold funding from an otherwise-approved, peer-reviewed project on ethical grounds unless an Ethics Advisory Board has first reviewed the project and advised the Secretary on it.

The Human Fetal Tissue Research Ethics Advisory Board

The Ethics Advisory Board (EAB) is a review body HHS can convene under §289g-1(b) to advise the Secretary on the ethics of specific HFT research proposals before funding decisions are made on ethical grounds. Its practical significance has varied considerably with administration policy rather than with any change to the underlying statute:

• In June 2019, HHS announced a policy (NIH Guide notice NOT-OD-20-053) ending new NIH intramural research using HFT obtained from elective abortions, and requiring new extramural grant applications proposing such research to undergo EAB review, in addition to ordinary NIH peer review, before any funding decision.
• In April 2021, HHS reversed the 2019 restrictions: it resumed intramural research using such tissue and stated it would not convene a new EAB, returning extramural applications to ordinary peer review without the added EAB layer.
• In January 2026, NIH announced it would end its support — across both the intramural program and extramural grant funding — for research using HFT obtained from elective abortions, a change that, as a practical matter, removes the funding pathway the EAB mechanism exists to review for this category of tissue.

Because this area has been revised multiple times by policy notice rather than by statute, the operative rule at any given moment is set by the current NIH Guide notice in force, not by this entry alone — research administrators should confirm current status directly against the NIH Guide for Grants and Contracts before relying on any specific date above for an active submission.

Relationship to 45 CFR 46 Subpart B

This NIH statutory and policy framework is separate from, but layered alongside, the human-subjects protections in 45 CFR 46 Subpart B. Subpart B §46.206 addresses IRB-level requirements for research on material obtained after delivery — the placenta, dead fetus, or fetal material — including compliance with applicable law on procurement, use, or disposal, and consent for use of identifiable information. The NIH framework described in this entry instead governs a narrower and more specific question: whether, and under what additional conditions, NIH will provide federal funding for research using HFT obtained specifically from elective abortions. A study can be subject to both frameworks simultaneously: IRB review under Subpart B for the human-subjects and biospecimen dimensions, and the NIH funding-eligibility conditions described here for the funding decision itself.

Frequently Asked Questions

Does this framework apply to all fetal tissue research, or only tissue from elective abortions?

The specific EAB-review and funding-restriction history described above has centered on HFT obtained from elective (induced) abortions. The general §289g-1(b) donation and consent conditions and 45 CFR 46.206’s applicable-law and consent requirements are not limited to that source category, but the contested funding-eligibility policy has been.

Is the Ethics Advisory Board currently active?

As of this entry’s publication, the EAB is not convened; the January 2026 NIH policy change ending funding for HFT research from elective abortions has, in practice, removed the funding pathway the EAB exists to review for that category. Research administrators should verify current status against the current NIH Guide notice before relying on this for an active submission.

Does state law also regulate human fetal tissue research?

Yes — §289g-2 and NIH policy operate alongside, not in place of, state laws governing the procurement, use, or disposal of fetal tissue, which vary by state and can independently restrict activity that federal policy would otherwise permit.

Related Terms

• 45 CFR 46 Subpart B (Additional Protections for Pregnant Women, Human Fetuses, and Neonates) — the Common Rule provisions this NIH funding framework sits alongside.
• Common Rule (45 CFR 46) — the general human-subjects regulation underlying Subpart B.
• OHRP (Office for Human Research Protections) — the HHS office administering Common Rule compliance, distinct from the NIH funding-eligibility policy described here.
• NIH Guidelines for Human Stem Cell Research — a comparable NIH administrative framework governing federal funding eligibility for a different, adjacent category of ethically contested research material.